Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab long-term safety in migraine
NCT02614287Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of galcanezumab in migraine, sponsored by Eli Lilly and Company. Started Nov 2015; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02614287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614287.